BILTRICIDE® (praziquantel) is a trematodicide provided in tablet form for the oral treatment of schistosome infections and infections due to liver fluke.
BILTRICIDE® is indicated for the treatment of infections due to: all species of schistosoma (e.g. Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated).
Published Studies Related to Biltricide (Praziquantel)
A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. [2011.06]
CONCLUSION: A higher dose of 60 mg/kg of praziquantel offers no significant efficacy advantage over standard 40 mg/kg for treating intestinal schistosomiasis caused by either S. mansoni or S. japonicum. The results of this study support WHO recommendation and should be used to inform policy decisions in the countries.
Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. [2011.04]
AIM: This study investigated the kinetic disposition, metabolism and enantioselectivity of albendazole (ABZ) and praziquantel (PZQ) administered alone and in combination to healthy volunteers... CONCLUSIONS: The pharmacokinetic interaction between ABZ and PZQ in healthy volunteers was demonstrated by the observation of increased plasma concentrations of ASON, both ASOX enantiomers and (-)-(R)-PZQ. Clinically, the combination of ABZ and PZQ may improve the therapeutic efficacy as a consequence of higher concentration of both active drugs. On the other hand, the magnitude of this elevation may represent an increased risk of side effects, requiring, certainly, reduction of the dosage. However, further studies are necessary to evaluate the efficacy and safety of this combination. (c) 2011 The Authors. British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological Society.
A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. [2011.04]
Integrated chemotherapy of neglected tropical diseases (NTD) through mass drug administration given as a single dose would increase treatment coverage and cost-effectiveness...
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. [2011.02]
BACKGROUND: Praziquantel is the only drug available for treatment of Opisthorchis viverrini, although in-vivo studies point to activity of mefloquine, artesunate, and tribendimidine against this liver fluke. We aimed to assess the efficacy and safety of these drugs compared with that of praziquantel in patients with O viverrini infection... INTERPRETATION: Tribendimidine seems to be at least as efficacious as the drug of choice, praziquantel, for the treatment of O viverrini infections; both drugs were well tolerated. Mefloquine, artesunate, and mefloquine-artesunate did not show an effect. Tribendimidine should be further investigated with large clinical trials. FUNDING: Swiss National Science Foundation, University of Basel. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Field trial of praziquantel for control of fishborne zoonotic trematodes in reservoir hosts in Vietnam. [2010.12.15]
This field trial was conducted to determine whether 40 or 75 mg/kg of praziquantel is suitable for treatment of fishborne zoonotic trematodes (FZT) in naturally infected dogs (n=10) and cats (n=11). Three days after treatment all animals at either dose were negative for small trematode eggs...
Clinical Trials Related to Biltricide (Praziquantel)
Praziquantel-Pharmacokinetic Study [Recruiting]
The purpose of the study is to understand whether the drug praziquantel (PZQ) is metabolized
or broken down differently when women are pregnant versus not pregnant. PZQ is used to treat
schistosomiasis (worm infection). Researchers will study how PZQ is broken down among 15
women who are 12-16 weeks pregnant, 15 women who are 30-36 weeks pregnant, and 15 women
nonpregnant women who are producing breast milk. All women will be 18 or older and otherwise
healthy. The usual practice is to wait until after mothers have finished pregnancy and
breast feeding before giving PZQ. Participants will receive 2 doses of PZQ separated by 3
hours. Study procedures will include a 24 hour hospital stay following administration of
PZQ, blood, stool and urine samples, ultrasound if pregnant, and physical exams of mother
and baby. Patient participation for mother/infant pair is about 9 months.
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil [Completed]
The primary objective of this project is to evaluate the efficacy and safety of praziquantel
60 mg/kg in the treatment of schistosomiasis, as compared to the standard 40 mg/kg therapy in
a representative community from a highly endemic area of schistosomiasis in Northeastern
Brazil. Cure rates, reduction in egg counts and proportions of reported side-effects in
children at the 10-19 y age-range with at least 100 eggs per gram of faeces will be compared
between regimens, aiming to evaluate the superiority of 60 mg/kg over the 40mg/kg dose
currently recommended by the WHO. Reinfection rates will also be evaluated aiming to improve
transmission control within the local health system, including re-treatment combined with
auxiliary control measures. Features related to the clinical, nutritional and immunological
status of the patients prior to treatment will also be investigated in association with the
outcome of praziquantel treatment.
Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis [Completed]
S. Japonicum and Pregnancy Outcomes [Recruiting]
The purpose of the study is to understand whether the drug praziquantel (PZQ) is safe for
the mother and developing baby when the mother has schistosomiasis (a type of worm)
infection, and whether the drug may improve the mother's and baby's health. The usual
practice is to wait until after a mother has finished breast feeding before giving the
medicine. Approximately 420 infected pregnant women, ages 18 and over, in endemic villages
in Leyte, The Philippines will participate. Study volunteers 12-16 weeks pregnant will be
given PZQ or an inactive pill (placebo) and stay in the hospital overnight. Small blood
samples will be collected before and after the medication is taken. Three stool and urine
samples will be taken during a total of 7 study visits. An ultrasound image (picture or
outline of the unborn baby) will be performed. When the baby is born, a small blood sample
will be taken. Mother and baby will be followed for up to 8 months before the baby is born
and 1 month after.
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda [Completed]
The overall objective of the project is to contribute to an increased knowledge about the
effect of praziquantel on schistosomiasis related morbidity and re-infection level among
communities living along Lake Victoria in Mayuge district, Uganda with the overall aim of
improving the strategies for morbidity control.
The study will be carried out in a high transmission area along Lake Victoria, in Mayuge
district. It will be a randomised intervention study, comparing a single praziquantel
treatment (40mg/kg) with two standard doses administered two weeks apart.
Reports of Suspected Biltricide (Praziquantel) Side Effects
Abdominal Pain (2),
Cytolytic Hepatitis (2),
Drug Ineffective (1),
Angioedema (1), more >>
Page last updated: 2011-12-09